Please use this identifier to cite or link to this item:
Title: Impact of high dose chemoimmunotherapy after surgery on the overall and disease-free survivals in u advanced stage malignant melanoma
Authors: Bilgin, Caglar
Cetinkunar, Suleyman
Bilgen, Koksal
Celep, Bahadir
Tokgoz, Serhat
Sozen, Selim
Karaca, Turgut
Ozer, Saadet
Tunc, Gunduz
Ordu Üniversitesi
Keywords: Adjuvant Chemotherapy Immunotherapy Malignant melanoma Surgery Survival
Issue Date: 2013
Abstract: BACKGROUND: To investigate the impact of high dose chemoimmunotherapy in addition to surgery on the cumulative survival and disease-free survey of malignant melanoma patients. METHODS: A total of 86 malignant melanoma patients [35 females (40.7%), 51 males (59.3%), mean age: 55.5] were treated according to their stages between Februrary 1997 and June 2007 After surgery, adjuvant immunotherapy was applied to patients in Stage 2, while adjuvant chemotherapy and adjuvan immunotherapy were administered to those at Stages 3 and 4. RESULTS: Overall rate of mortality was 31.4% (27/86). The most frequent postoperative complications were wound infection (n=8, 9.3%) in the early period and lymphedema in lower extremities (n=4, 4.6%) in the late period. Temporary and tolerable complications ensourcing from chemoimmunotherapy were encountered in 9 (10.4%) patients. The survival rates and disease-free periods of combined treatment protocol were found to be similar to those in ECOG 1684 and ECOG 1690 studies. CONCLUSION: Adjuvant immunotherapy and chemoimmunotherapy seem to improve overall survival and disease-free survey in malignant melanoma. Further clinical studies are necessary to demonstrate the actual effectivity of this promising protocol in the management of malignant melanoma.
Appears in Collections:Cerrahi Tıp Bilimleri

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.